Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis

Current Cancer Drug Targets

Volumn 14, Issue 6, 2014, Pages 567-588

  Huang, Wen Qing ^a   Lin, Qing ^a,b   Zhuang, Xuan ^b   Cai, Liang Liang ^a   Ruan, Run Sheng ^a   Lu, Zhong Xian ^a   Tzeng, Chi Meng ^a  

^a XIAMEN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Hematologic malignancies; LEOPARD syndrome; Noonan syndromes; PTPN11; SHP2; Tumorigenesis

Indexed keywords

JANUS KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT PROTEIN; STAT5 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; DEVELOPMENTAL DISORDER; DOWNSTREAM PROCESSING; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; LEOPARD SYNDROME; LEUKEMIA; LIVER CELL CARCINOMA; NONHUMAN; PATHOGENESIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; SRC HOMOLOGY DOMAIN; STOMACH CANCER; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); GENE EXPRESSION; NOONAN SYNDROME; PROTEIN FUNCTION; PROTEIN STRUCTURE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS; PATHOLOGY; PHENOTYPE; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; ENZYME INHIBITORS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEOPARD SYNDROME; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; NOONAN SYNDROME; PHENOTYPE; PROTEIN CONFORMATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907345106     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140717105001     Document Type: Article

References (217)

1. Sastry, S.K.; Elferink, L.A. Checks and balances: interplay of RTKs and PTPs in cancer progression. Biochem. Pharmacol., 2011, 82, 435-440.
2. Neel, B.G.; Gu, H.; Pao, L. The 'Shp'ing news: SH2 domaincontaining tyrosine phosphatases in cell signaling. Trends Biochem. Sci., 2003, 28, 284-293.
3. Qu, C.K. The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. Cell Res., 2000, 10, 279-288.
4. Julien, S.G.; Dube, N.; Hardy, S.; Tremblay, M.L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer, 2011, 11, 35-49.
5. Tartaglia, M.; Gelb, B.D. Noonan syndrome and related disorders: genetics and pathogenesis. Annu. Rev. Genomics. Hum. Genet., 2005, 6, 45-68.
6. Liu, X.; Qu, C.K. Protein Tyrosine Phosphatase SHP-2 (PTPN11) in hematopoiesis and leukemogenesis. J. Signal Transduct., 2011, 2011, 195-239.
7. Chan, G.; Kalaitzidis, D.; Neel, B.G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis. Rev., 2008, 27, 179-192.
8. Mohi, M.G.; Neel, B.G. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev., 2007, 17, 23-30.
9. Li, S.; Hsu, D.D.; Wang, H.; Feng, G.S. Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis. Front. Med., 2012, 6, 275-279.
10. Tartaglia, M.; Gelb, B.D. Germ-line and somatic PTPN11 mutations in human disease. Eur. J. Med. Genet., 2005, 48, 81-96.
11. Tartaglia, M.; Martinelli, S.; Stella, L.; Bocchinfuso, G.; Flex, E.; Cordeddu, V.; Zampino, G.; Burgt, I; Palleschi, A.; Petrucci, T.C.; Sorcini, M.; Schoch, C.; Foa, R.; Emanuel, P.D.; Gelb, B.D. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet., 2006, 78, 279-290.
12. Barr, A.J. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med. Chem., 2010, 2, 1563-1576.
13. Nguyen, L.K.; Matallanas, D.; Croucher, D.R.; von Kriegsheim, A.; Kholodenko, B.N. Signalling by protein phosphatases and drug development: a systems-centred view. FEBS J., 2013, 280, 751-765.
14. He, R.; Zeng, L.F.; He, Y.; Zhang, S.; Zhang, Z.Y. Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J., 2013, 280, 731-750.
15. Freeman, R.M. Jr.; Plutzky, J.; Neel, B.G. Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. Proc. Natl. Acad. Sci. U S A., 1992, 89, 11239-11243.
16. Ahmad, S.; Banville, D.; Zhao, Z.; Fischer, E.H.; Shen, S.H. A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains. Proc. Natl. Acad. Sci. U S A., 1993, 90, 2197-2201.
17. Hof, P.; Pluskey, S.; Dhe-Paganon, S.; Eck, M.J.; Shoelson, S.E. Crystal structure of the tyrosine phosphatase SHP-2. Cell., 1998, 92, 441-450.
18. Matozaki, T.; Murata, Y.; Saito, Y.; Okazawa, H.; Ohnishi, H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci., 2009, 100, 1786-1793.
19. Scott, L.M.; Lawrence, H.R.; Sebti, S.M.; Lawrence, N.J.; Wu, J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr. Pharm. Des., 2010, 16, 1843-1862.
20. Xu, D.; Qu, C.K. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci., 2008, 13, 4925-4932.
21. Vogel, W.; Lammers, R.; Huang, J.; Ullrich, A. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science, 1993, 259, 1611-1614.
22. Feng, G.S.; Hui, C.C.; Pawson, T. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science, 1993, 259, 1607-1611.
23. Sun, J.; Lu, S.; Ouyang, M.; Lin, L.J.; Zhuo, Y.; Liu, B.; Chien, S.; Neel, B.G.; Wang, Y. Antagonism between binding site affinity and conformational dynamics tunes alternative cis-interactions within Shp2. Nat. Commun., 2013, 4, 2037.
24. Martinelli, S.; Torreri, P.; Tinti, M.; Stella, L.; Bocchinfuso, G.; Flex, E.; Grottesi, A.; Ceccarini, M.; Palleschi, A.; Cesareni, G.; Castagnoli, L.; Petrucci, T.C.; Gelb, B.D.; Tartaglia, M. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum. Mol. Genet., 2008, 17, 2018-2029.
25. Martinelli, S.; Nardozza, A.P.; Delle Vigne, S.; Sabetta, G.; Torreri, P.; Bocchinfuso, G.; Flex, E.; Venanzi, S.; Palleschi, A.; Gelb, B.D.; Cesareni, G.; Stella, L.; Castagnoli, L.; Tartaglia, M. Counteracting effects operating on Src homology 2 domaincontaining protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome. J. Biol. Chem., 2012, 287, 27066-27077.
26. Kontaridis, M.I.; Swanson, K.D.; David, F.S.; Barford D.; Neel, B.G. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem., 2006, 281, 6785-6792.
27. Yu, Z.H; Xu, J.; Walls, C.D.; Chen, L.; Zhang, S.; Zhang, R.; Wu, L.; Wang, L.; Liu, S.; Zhang, Z.Y. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J. Biol. Chem., 2013, 288, 10472-10482.
28. Muller, P.J.; Rigbolt, K.T.; Paterok, D.; Piehler, J.; Vanselow, J.; Lasonder, E.; Andersen, J.S.; Schaper, F.; Sobota, R.M. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia. J. Proteomics, 2013, 84, 132-147.
29. Chong, Z.Z.; Maiese, K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol. Histopathol., 2007, 22, 1251-1267.
30. Yu, D.H.; Qu, C.K.; Henegariu, O.; Lu, X.; Feng, G.S. Proteintyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J. Biol. Chem., 1998, 273, 21125-21131.
31. Dance, M.; Montagner, A.; Salles, J.P.; Yart, A.; Raynal, P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal., 2008, 20, 453-459.
32. Agazie, Y.M.; Hayman, M.J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol. Cell. Biol., 2003, 23, 7875-7886.
33. Bennett, A.M.; Tang, T.L.; Sugimoto, S.; Walsh, C.T.; Neel, B.G. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc. Natl. Acad. Sci. U S A., 1994, 91, 7335-7339.
34. Noguchi, T.; Matozaki, T.; Horita, K.; Fujioka, Y.; Kasuga, M. Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. Mol. Cell. Biol., 1994, 14, 6674-6682.
35. Montagner, A.; Yart, A.; Dance, M.; Perret, B.; Salles, J.P.; Raynal, P. A novel role for Gab1 and SHP2 in epidermal growth factorinduced Ras activation. J. Biol. Chem., 2005, 280, 5350-5360.
36. Zhou, X.; Agazie, Y.M. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J. Biol. Chem., 2009, 284, 12226-12234.
37. Ren, Y.; Meng, S.; Mei, L.; Zhao, Z.J.; Jove, R.; Wu, J. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J. Biol. Chem., 2004, 279, 8497-8505.
38. Zhang, S.Q.; Yang, W.; Kontaridis, M.I.; Bivona, T.G.; Wen, G.; Araki, T.; Luo, J.; Thompson, J.A.; Schraven, B.L.; Philips, M.R.; Neel, B.G. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell, 2004, 13, 341-355.
39. Hanafusa, H.; Torii, S.; Yasunaga, T.; Nishida, E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol., 2002, 4, 850-858.
40. Hanafusa, H.; Torii, S.; Yasunaga, T.; Matsumoto, K.; Nishida, E. Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. J. Biol. Chem., 2004, 279, 22992-22995.
41. Jarvis, L.A.; Toering, S.J.; Simon, M.A.; Krasnow, M.A.; Smith-Bolton, R.K. Sprouty proteins are in vivo targets of Corkscrew/ SHP-2 tyrosine phosphatases. Development, 2006, 133, 1133-1142.
42. Nonami, A.; Kato, R.; Taniguchi, K.; Yoshiga, D.; Taketomi, T.; Fukuyama, S.; Harada, M.; Sasaki, A.; Yoshimura, A. Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells. J. Biol. Chem., 2004, 279, 52543-52551.
43. Wakioka, T.; Sasaki, A.; Kato, R.; Shouda, T.; Matsumoto, A.; Miyoshi, K.; Tsuneoka, M.; Komiya, S.; Baron, R.; Yoshimura, A. Spred is a Sprouty-related suppressor of Ras signalling. Nature, 2001, 412, 647-651.
44. Huang, W.; Saberwal, G.; Horvath, E.; Zhu, C.; Lindsey, S.; Eklund, E.A. Leukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding protein. Mol. Cell. Biol., 2006, 26, 6311-6332.
45. Cunnick, J.M.; Mei, L.; Doupnik, C.A.; Wu, J. Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J. Biol. Chem., 2001, 276, 24380-24387.
46. Bentires-Alj, M.; Gil, S.G.; Chan, R.; Wang, Z.C.; Wang, Y.; Imanaka, N.; Harris, L.N.; Richardson, A.; Neel, B.G.; Gu, H. A role for the scaffolding adapter GAB2 in breast cancer. Nat. Med., 2006, 12, 114-121.
47. Cai, T.; Nishida, K.; Hirano, T.; Khavari, P.A. Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation. J.Cell. Biol., 2002, 159, 103-112.
48. Kuhne, M.R.; Pawson, T.; Lienhard, G.E.; Feng, G.S. The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase Syp. J. Biol. Chem., 1993, 268, 11479-11481.
49. Hadari, Y.R.; Kouhara, H.; Lax, I.; Schlessinger, J. Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol. Cell. Biol., 1998, 18, 3966-3973.
50. Kazlauskas, A.; Feng, G.S.; Pawson, T.; Valius, M. The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp. Proc. Natl. Acad. Sci. U S A., 1993, 90, 6939-6943.
51. Fujioka, Y.; Matozaki, T.; Noguchi, T.; Iwamatsu, A.; Yamao, T.; Takahashi, N.; Tsuda, M.; Takada, T.; Kasuga, M. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domaincontaining protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol. Cell. Biol., 1996, 16, 6887-6899.
52. Zhao, R.; Zhao, Z.J. Dissecting the interaction of SHP-2 with PZR, an immunoglobulin family protein containing immunoreceptor tyrosine-based inhibitory motifs. J. Biol. Chem., 2000, 275, 5453-5459.
53. Jackson, D.E.; Ward, C.M.; Wang, R.; Newman, P.J. The proteintyrosine phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-1 (PECAM-1) and forms a distinct signaling complex during platelet aggregation. Evidence for a mechanistic link between PECAM-1-and integrin-mediated cellular signaling. J. Biol. Chem., 1997, 272, 6986-6993.
54. Vogel, W.; Ullrich, A. Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584. Cell Growth Differ., 1996, 7, 1589-1597.
55. Cunnick, J.M.; Meng, S.; Ren, Y.; Desponts, C.; Wang, H.G.; Djeu, J.Y.; Wu, J. Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J. Biol. Chem., 2002, 277, 9498-9504.
56. Meng, S.; Chen, Z.; Munoz-Antonia, T.; Wu, J. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor. Biochem. J., 2005, 391, 143-151.
57. Ahmed, Z.; Lin, C.C.; Suen, K.M.; Melo, F.A.; Levitt, J.A.; Suhling, K.; Ladbury, J.E. Grb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activity. J. Cell. Biol., 2013, 200, 493-504.
58. Tsutsumi, R.; Masoudi, M.; Takahashi, A.; Fujii, Y.; Hayashi, T.; Kikuchi, I.; Satou, Y.; Taira, M.; Hatakeyama, M. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. Dev. Cell., 2013, 26, 658-665.
59. Draber, P.; Stepanek, O.; Hrdinka, M.; Drobek, A.; Chmatal, L.; Mala, L.; Ormsby, T.; Angelisova, P.; Horejsi, V.; Brdicka, T. LST1/A is a myeloid leukocyte-specific transmembrane adaptor protein recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to the plasma membrane. J. Biol. Chem., 2012, 287, 22812-22821.
60. Okur, M.N.; Russo, A.; O'Bryan, J.P. Receptor tyrosine kinase ubiquitylation involves the dynamic regulation of Cbl-Spry2 by intersectin 1 and the Shp2 tyrosine phosphatase. Mol. Cell. Biol., 2014, 34, 271-279.
61. Craig, J.; Mikhailenko, I.; Noyes, N.; Migliorini, M.; Strickland, D.K. The LDL receptor-related protein 1 (LRP1) regulates the PDGF signaling pathway by binding the protein phosphatase SHP-2 and modulating SHP-2-mediated PDGF signaling events. PLoS One., 2013, 8, e70432.
62. Wu, T.R.; Hong, Y.K.; Wang, X.D.; Ling, M.Y.; Dragoi, A.M.; Chung, A.S.; Campbell, A.G.; Han, Z.Y.; Feng, G.S.; Chin, Y.E. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J. Biol. Chem., 2002, 277, 47572-47580.
63. Chen, Y.; Wen, R.; Yang, S.; Schuman, J.; Zhang, E.E.; Yi, T.; Feng, G.S.; Wang, D. Identification of Shp-2 as a Stat5A phosphatase. J. Biol. Chem., 2003, 278, 16520-16527.
64. Peng, Z.Y.; Cartwright, C.A. Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association. Oncogene, 1995, 11, 1955-1962.
65. Takahashi, A.; Tsutsumi, R.; Kikuchi, I.; Obuse, C.; Saito, Y.; Seidi, A.; Karisch, R.; Fernandez, M.; Cho, T.; Ohnishi, N.; Rozenblatt-Rosen, O.; Meyerson, M.; Neel, B.G.; Hatakeyama, M. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol. Cell., 2011, 43, 45-56.
66. Watanabe, N.; Kato, T.; Fujita, H.; Kitagawa, S. Heterogeneous nuclear ribonucleoprotein Q is a novel substrate of SH2 domaincontaining phosphatase-2. J. Biochem., 2013, 154, 475-480.
67. Xu, D.; Zheng, H.; Yu, W.M.; Qu, C.K. Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder. PLoS One, 2013, 8, e63152.
68. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103, 211-225.
69. Kwon, M.; Ling, Y.; Maile, L.A.; Badley-Clark, J.; Clemmons, D.R. Recruitment of the tyrosine phosphatase Src homology 2 domain tyrosine phosphatase-2 to the p85 subunit of phosphatidylinositol-3 (PI-3) kinase is required for insulin-like growth factor-I-dependent PI-3 kinase activation in smooth muscle cells. Endocrinology, 2006, 147, 1458-1465.
70. Laramee, M.; Chabot, C.; Cloutier, M.; Stenne, R.; Holgado-Madruga, M.; Wong, A.J; Royal, I. The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation. J. Biol. Chem., 2007, 282, 7758-7769.
71. Burks, J.; Agazie, Y.M. Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3. Oncogene, 2006, 25, 7166-7179.
72. Agazie, Y.M.; Movilla, N.; Ischenko, I.; Hayman, M.J. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene, 2003, 22, 6909-6918.
73. Ivins Zito, C.; Kontaridis, M.I.; Fornaro, M.; Feng, G.S.; Bennett, A.M. SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis. J. Cell. Physiol., 2004, 199, 227-236.
74. Li, W.; Nishimura, R.; Kashishian, A.; Batzer, A.G; Kim, W.J; Cooper, J.A; Schlessinger, J. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol. Cell. Biol., 1994, 14, 509-517.
75. Klinghoffer, R.A.; Duckworth, B.; Valius, M.; Cantley, L.; Kazlauskas, A. Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol. Cell. Biol., 1996, 16, 5905-5914.
76. Mattoon, D.R.; Lamothe, B.; Lax, I.; Schlessinger, J. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol., 2004, 2, 24.
77. Zhang, S.Q.; Tsiaras, W.G.; Araki, T.; Wen, G.; Minichiello, L.; Klein, R.; Neel, B.G. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. Mol. Cell. Biol., 2002, 22, 4062-4072.
78. Ali, S.; Nouhi, Z.; Chughtai, N. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor. J. Biol. Chem., 2003, 278, 52021-52031.
79. Ke, Y.; Lesperance, J.; Zhang, E.E.; Bard-Chapeau, E.A.; Oshima, R.G.; Muller, W.J.; Feng, G.S. Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation. J. Biol. Chem., 2006, 281, 34374-34380.
80. Chan, R.J.; Johnson, S.A.; Li, Y.; Yoder, M.C.; Feng, G.S. A definitive role of Shp-2 tyrosine phosphatase in mediating embryonic stem cell differentiation and hematopoiesis. Blood, 2003, 102, 2074-2080.
81. Niwa, H.; Burdon, T.; Chambers, I.; Smith, A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev., 1998, 12, 2048-2060.
82. Ke, Y.; Zhang, E.E.; Hagihara, K.; Wu, D.; Pang, Y.; Klein, R.; Curran, T.; Ranscht, B.; Feng, G.S. Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol. Cell. Biol., 2007, 27, 6706-6717.
83. Bard-Chapeau, E.A.; Li, S.; Ding, J.; Zhang, S.S.; Zhu, H.H.; Princen, F.; Fang, D.D.; Han, T.; Bailly-Maitre, B.; Poli, V.; Varki, N.M.; Wang, H.; Feng, G.S. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell, 2011, 19, 629-639.
84. You, M.; Yu, D.H.; Feng, G.S. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol., 1999, 19, 2416-2424.
85. Yu, C.L.; Jin, Y.J.; Burakoff, S.J. Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation. J. Biol. Chem., 2000, 275, 599-604.
86. Chen, J.; Yu, W.M.; Bunting, K.D.; Qu, C.K. A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival. Oncogene, 2004, 23, 3659-3669.
87. Chughtai, N.; Schimchowitsch, S.; Lebrun, J.J.; Ali, S. Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J. Biol. Chem., 2002, 277, 31107-31114.
88. Jakob, S.; Schroeder, P.; Lukosz, M.; Buchner, N.; Spyridopoulos, I.; Altschmied, J.; Haendeler, J. Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase. J. Biol. Chem., 2008, 283, 33155-33161.
89. Haendeler, J.; Hoffmann, J.; Diehl, J.F.; Vasa, M.; Spyridopoulos, I.; Zeiher, A.M.; Dimmeler, S. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ. Res., 2004, 94, 768-775.
90. Yuan, L.; Yu, W.M.; Yuan, Z.; Haudenschild, C.C.; Qu, C.K. Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response. J. Biol. Chem., 2003, 278, 15208-15216.
91. Yuan, L.; Yu, W.M.; Xu, M.; Qu, C.K. SHP-2 phosphatase regulates DNA damage-induced apoptosis and G2/M arrest in catalytically dependent and independent manners, respectively. J. Biol. Chem., 2005, 280, 42701-42706.
92. Mosimann, C.; Hausmann, G.; Basler, K. Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell, 2006, 125, 327-341.
93. Oh, H.; Taffet, G.E.; Youker, K.A.; Entman, M.L.; Overbeek, P.A.; Michael, L.H.; Schneider, M.D. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc. Natl. Acad. Sci. U S A., 2001, 98, 10308-10313.
94. Huang, Q.; Lerner-Marmarosh, N.; Che, W.; Ohta, S.; Osawa, M.; Yoshizumi, M.; Glassman, M.; Yan, C.; Berk, B.C.; Abe, J. The novel role of the C-terminal region of SHP-2. Involvement of Gab1 and SHP-2 phosphatase activity in Elk-1 activation. J. Biol. Chem., 2002, 277, 29330-29341.
95. Osawa, M.; Itoh, S.; Ohta, S.; Huang, Q.; Berk, B.C.; Marmarosh, N.L.; Che, W.; Ding, B.; Yan, C.; Abe, J. ERK1/2 associates with the c-Met-binding domain of growth factor receptor-bound protein 2 (Grb2)-associated binder-1 (Gab1): role in ERK1/2 and early growth response factor-1 (Egr-1) nuclear accumulation. J. Biol. Chem., 2004, 279, 29691-29699.
96. Uhlen, P.; Burch, P.M.; Zito, C.I.; Estrada, M.; Ehrlich, B.E.; Bennett, A.M. Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling. Proc. Natl. Acad. Sci. U S A., 2006, 103, 2160-2165.
97. Shi, Z.Q.; Lu, W.; Feng, G.S. The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signalregulated and c-Jun NH2-terminal mitogen-activated protein kinases. J. Biol. Chem., 1998, 273, 4904-4908.
98. Kontaridis, M.I.; Eminaga, S.; Fornaro, M.; Zito, C.I.; Sordella, R.; Settleman, J.; Bennett, A.M. SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway. Mol. Cell. Biol., 2004, 24, 5340-5352.
99. Yang, W.; Wang, J.; Moore, D.C.; Liang, H.; Dooner, M.; Wu, Q.; Terek, R.; Chen, Q.; Ehrlich, M.G.; Quesenberry, P.J.; Neel, B.G. Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature, 2013, 499, 491-495.
100. Kapoor, G.S.; Zhan, Y.; Johnson, G.R.; O'Rourke, D.M. Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol. Cell. Biol., 2004, 24, 823-836.
101. Fukunaga, K.; Noguchi, T.; Takeda, H.; Matozaki, T.; Hayashi, Y.; Itoh, H.; Kasuga, M. Requirement for protein-tyrosine phosphatase SHP-2 in insulin-induced activation of c-Jun NH(2)-terminal kinase. J. Biol. Chem., 2000, 275, 5208-5213.
102. Kontaridis, M.I.; Yang, W.; Bence, K.K.; Cullen, D.; Wang, B.; Bodyak, N.; Ke, Q.; Hinek, A.; Kang, P.M.; Liao, R.; Neel, B.G. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. Circulation, 2008, 117, 1423-1435.
103. He, Z.; Zhu, H.H.; Bauler, T.J.; Wang, J.; Ciaraldi, T.; Alderson, N.; Li, S.; Raquil, M.A.; Ji, K.; Wang, S.; Shao, J.; Henry, R.R.; King, P.D.; Feng, G.S. Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc. Natl. Acad. Sci. U S A., 2013, 110, E79-E88.
104. Qu, C.K.; Nguyen, S.; Chen, J.; Feng, G.S. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood, 2001, 97, 911-914.
105. Chan, G.; Cheung, L.S.; Yang, W.; Milyavsky, M.; Sanders, A.D.; Gu, S.; Hong, W.X.; Liu, A.X.; Wang, X.; Barbara, M.; Sharma, T.; Gavin, J.; Kutok, J.L.; Iscove, N.N.; Shannon, K.M.; Dick, J.E.; Neel, B.G.; Braun, B.S. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood, 2011, 117, 4253-4261.
106. Saxton, T.M.; Ciruna, B.G.; Holmyard, D.; Kulkarni, S.; Harpal, K.; Rossant, J.; Pawson, T. The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nat. Genet, 2000, 24, 420-423.
107. Jopling, C.; van Geemen, D.; den Hertog, J. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects. PLoS Genet., 2007, 3, e225.
108. Bonetti, M.; Rodriguez-Martinez, V.; Paardekooper Overman, J.; Overvoorde, J.; van Eekelen, M.; Jopling, C.; Hertog, J. Distinct and Overlapping Functions of ptpn11 Genes in Zebrafish Development. PLoS One, 2014, 9, e94884.
109. Tartaglia, M.; Mehler, E.L.; Goldberg, R.; Zampino, G.; Brunner, H.G.; Kremer, H.; van der Burgt, I.; Crosby, A.H.; Ion, A.; Jeffery, S.; Kalidas, K.; Patton, M.A.; Kucherlapati, R.S.; Gelb, B.D. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet., 2001, 29, 465-468.
110. Tartaglia, M.; Zampino, G.; Gelb, B.D. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol. Syndromol., 2010, 1, 2-26.
111. Lauriol, J.; Kontaridis, M.I. PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? Trends Cardiovasc. Med., 2011, 21, 97-104.
112. Sarkozy, A.; Digilio, M.C.; Dallapiccola, B. Leopard syndrome. Orphanet. J. Rare Dis., 2008, 3, 13.
113. Legius, E.; Schrander-Stumpel, C.; Schollen, E.; Pulles-Heintzberger, C.; Gewillig, M.; Fryns, J.P. PTPN11 mutations in LEOPARD syndrome. J. Med. Genet., 2002, 39, 571-574.
114. Loh, M.L.; Vattikuti, S.; Schubbert, S.; Reynolds, M.G.; Carlson, E.; Lieuw, K.H.; Cheng, J.W.; Lee, C.M.; Stokoe, D.; Bonifas, J.M.; Curtiss, N.P.; Gotlib, J.; Meshinchi, S.; Le Beau, M.M.; Emanuel, P.D.; Shannon, K.M. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 2004, 103, 2325-2331.
115. Tartaglia, M.; Niemeyer, C.M.; Fragale, A.; Song, X.; Buechner, J.; Jung, A.; Hahlen, K.; Hasle, H.; Licht, J.D.; Gelb, B.D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet., 2003, 34, 148-150.
116. Tartaglia, M.; Martinelli, S.; Cazzaniga, G.; Cordeddu, V.; Iavarone, I.; Spinelli, M.; Palmi, C.; Carta, C.; Pession, A.; Arico, M.; Masera, G.; Basso, G.; Sorcini, M.; Gelb, B.D.; Biondi, A. Genetic evidence for lineage-related and differentiation stagerelated contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood, 2004, 104, 307-313.
117. Loh, M.L.; Reynolds, M.G.; Vattikuti, S.; Gerbing, R.B.; Alonzo, T.A.; Carlson, E.; Cheng, J.W.; Lee, C.M.; Lange, B.J.; Meshinchi, S.; Children's Cancer, G. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia, 2004, 18, 1831-1834.
118. Shchelochkov, O.A.; Patel, A.; Weissenberger, G.M.; Chinault, A.C.; Wiszniewska, J.; Fernandes, P.H.; Eng, C.; Kukolich, M.K.; Sutton, V.R. Duplication of chromosome band 12q24.11q24.23 results in apparent Noonan syndrome. Am. J. Med. Genet. A., 2008, 146A, 1042-1048.
119. Graham, J.M. Jr.; Kramer, N.; Bejjani, B.A.; Thiel, C.T.; Carta, C.; Neri, G.; Tartaglia, M.; Zenker, M. Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome. Am. J. Med. Genet. A., 2009, 149A, 2122-2128.
120. Chen, J.L.; Zhu, X.; Zhao, T.L.; Wang, J.; Yang, Y.F.; Tan, Z.P. Rare copy number variations containing genes involved in RASopathies: deletion of SHOC2 and duplication of PTPN11. Mol. Cytogenet., 2014, 7, 28.
121. Romano, A.A.; Allanson, J.E.; Dahlgren, J.; Gelb, B.D.; Hall, B.; Pierpont, M.E.; Roberts, A.E.; Robinson, W.; Takemoto, C.M.; Noonan, J.A. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics, 2010, 126, 746-759.
122. Qiu, W.; Wang, X.; Romanov, V.; Hutchinson, A.; Lin, A.; Ruzanov, M.; Battaile, K.P.; Pai, E.F.; Neel, B.G.; Chirgadze, N.Y. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). BMC Struct. Biol., 2014, 14, 10.
123. Keilhack, H.; David, F.S.; McGregor, M.; Cantley, L.C.; Neel, B.G. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J. Biol. Chem., 2005, 280, 30984-30993.
124. Nakamura, T.; Gulick, J.; Pratt, R.; Robbins, J. Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations. Proc. Natl. Acad. Sci. U S A., 2009, 106, 15436-15441.
125. De Rocca Serra-Nedelec, A.; Edouard, T.; Treguer, K.; Tajan, M.; Araki, T.; Dance, M.; Mus, M.; Montagner, A.; Tauber, M.; Salles, J.P.; Valet, P.; Neel, B.G.; Raynal, P.; Yart, A. Noonan syndromecausing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature. Proc. Natl. Acad. Sci. U S A., 2012, 109, 4257-4262.
126. Araki, T.; Chan, G.; Newbigging, S.; Morikawa, L.; Bronson, R.T.; Neel, B.G. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardialmesenchymal transformation. Proc. Natl. Acad. Sci. U S A., 2009, 106, 4736-4741.
127. Nakamura, T.; Colbert, M.; Krenz, M.; Molkentin, J.D.; Hahn, H.S.; Dorn, G.W. 2nd.; Robbins, J. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J. Clin. Invest., 2007, 117, 2123-2132.
128. Krenz, M.; Gulick, J.; Osinska, H.E.; Colbert, M.C.; Molkentin, J.D.; Robbins, J. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome. Proc. Natl. Acad. Sci. U S A., 2008, 105, 18930-18935.
129. Araki, T.; Mohi, M.G.; Ismat, F.A.; Bronson, R.T.; Williams, I.R.; Kutok, J.L.; Yang, W.; Pao, L.I.; Gilliland, D.G.; Epstein, J.A.; Neel, B.G. Mouse model of Noonan syndrome reveals cell typeand gene dosage-dependent effects of Ptpn11 mutation. Nat. Med., 2004, 10, 849-857.
130. Bonetti, M.; Paardekooper Overman, J.; Tessadori, F.; Noel, E.; Bakkers, J.; den Hertog, J. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish. Development, 2014, 141, 1961-1970.
131. Krenz, M.; Yutzey, K.E.; Robbins, J. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling. Circ. Res., 2005, 97, 813-820.
132. Hanna, N.; Montagner, A.; Lee, W.H.; Miteva, M.; Vidal, M.; Vidaud, M.; Parfait, B.; Raynal, P. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett., 2006, 580, 2477-2482.
133. Marin, T.M.; Keith, K.; Davies, B.; Conner, D.A.; Guha, P.; Kalaitzidis, D.; Wu, X.; Lauriol, J.; Wang, B.; Bauer, M.; Bronson, R.; Franchini, K.G.; Neel, B.G.; Kontaridis, M.I. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest., 2011, 121, 1026-1043.
134. Carvajal-Vergara, X.; Sevilla, A.; D'Souza, S.L.; Ang, Y.S.; Schaniel, C.; Lee, D.F.; Yang, L.; Kaplan, A.D.; Adler, E.D.; Rozov, R.; Ge, Y.; Cohen, N.; Edelmann, L.J.; Chang, B.; Waghray, A.; Su, J.; Pardo, S.; Lichtenbelt, K.D.; Tartaglia, M.; Gelb, B.D.; Lemischka, I.R. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature, 2010, 465, 808-812.
135. Oishi, K.; Zhang, H.; Gault, W.J.; Wang, C.J.; Tan, C.C.; Kim, I.K.; Ying, H.; Rahman, T.; Pica, N.; Tartaglia, M.; Mlodzik, M.; Gelb, B.D. Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum. Mol. Genet., 2009, 18,193-201.
136. Pandit, B.; Sarkozy, A.; Pennacchio, L.A.; Carta, C.; Oishi, K.; Martinelli, S.; Pogna, E.A.; Schackwitz, W.; Ustaszewska, A.; Landstrom, A.; Bos, J.M.; Ommen, S.R.; Esposito, G.; Lepri, F.; Faul, C.; Mundel, P.; Lopez Siguero, J.P.; Tenconi, R.; Selicorni, A.; Rossi, C.; Mazzanti, L.; Torrente, I.; Marino, B.; Digilio, M.C.; Zampino, G.; Ackerman, M.J.; Dallapiccola, B.; Tartaglia, M.; Gelb, B.D. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat. Genet., 2007, 39, 1007-1012.
137. Edouard, T.; Combier, J.P.; Nedelec, A.; Bel-Vialar, S.; Metrich, M.; Conte-Auriol, F.; Lyonnet, S.; Parfait, B.; Tauber, M.; Salles, J.P.; Lezoualc'h, F.; Yart, A.; Raynal, P. Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling. Mol. Cell. Biol., 2010, 30, 2498-2507.
138. Ishida, H.; Kogaki, S.; Narita, J.; Ichimori, H.; Nawa, N.; Okada, Y.; Takahashi, K.; Ozono, K. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3beta/betacatenin signaling. Am. J. Physiol. Heart Circ. Physiol., 2011, 301, H1531-H1539.
139. Schramm, C.; Fine, D.M.; Edwards, M.A.; Reeb, A.N.; Krenz, M. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling. Am. J. Physiol. Heart Circ. Physiol., 2012, 302, H231-H243.
140. Qu, C.K.; Shi, Z.Q.; Shen, R.; Tsai, F.Y.; Orkin, S.H.; Feng, G.S. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol. Cell. Biol., 1997, 17, 5499-5507.
141. Qu, C.K.; Yu, W.M.; Azzarelli, B.; Cooper, S.; Broxmeyer, H.E.; Feng, G.S. Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol. Cell. Biol., 1998, 18, 6075-6082.
142. Tartaglia, M.; Niemeyer, C.M.; Shannon, K.M.; Loh, M.L. SHP-2 and myeloid malignancies. Curr. Opin. Hematol., 2004, 11, 44-50.
143. Johan, M.F.; Bowen, D.T.; Frew, M.E.; Goodeve, A.C.; Wilson, G.A.; Peake, I.R.; Reilly, J.T. Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia. Br. J. Haematol., 2004, 124, 843-844.
144. Watkins, F.; Fidler, C.; Boultwood, J.; Wainscoat, J.S. Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia. Am. J. Hematol., 2004, 76, 417.
145. Loh, M.L.; Martinelli, S.; Cordeddu, V.; Reynolds, M.G.; Vattikuti, S.; Lee, C.M.; Wulfert, M.; Germing, U.; Haas, P.; Niemeyer, C.; Beran, M.E.; Strom, S.; Lubbert, M.; Sorcini, M.; Estey, E.H.; Gattermann, N.; Tartaglia, M. Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk. Res., 2005, 29, 459-462.
146. Bader-Meunier, B.; Tchernia, G.; Mielot, F.; Fontaine, J.L.; Thomas, C.; Lyonnet, S.; Lavergne, J.M.; Dommergues, J.P. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J. Pediatr., 1997, 130, 885-889.
147. Choong, K.; Freedman, M.H.; Chitayat, D.; Kelly, E.N.; Taylor, G.; Zipursky, A. Juvenile myelomonocytic leukemia and Noonan syndrome. J. Pediatr. Hematol. Oncol., 1999, 21, 523-527.
148. Hasle, H. Malignant diseases in Noonan syndrome and related disorders. Horm. Res., 2009, 72 Suppl 2, 8-14.
149. Side, L.E.; Shannon, K.M. Myeloid disorders in infants with Noonan syndrome and a resident's rule recalled. J. Pediatr., 1997, 130, 857-859.
150. Bentires-Alj, M.; Paez, J.G.; David, F.S.; Keilhack, H.; Halmos, B.; Naoki, K.; Maris, J.M.; Richardson, A.; Bardelli, A.; Sugarbaker, D.J.; Richards, W.G.; Du, J.; Girard, L.; Minna, J.D.; Loh, M.L.; Fisher, D.E.; Velculescu, V.E.; Vogelstein, B.; Meyerson, M.; Sellers, W.R.; Neel, B.G. Activating mutations of the noonan syndromeassociated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res., 2004, 64, 8816-8820.
151. Mohi, M.G.; Williams, I.R.; Dearolf, C.R.; Chan, G.; Kutok, J.L.; Cohen, S.; Morgan, K.; Boulton, C.; Shigematsu, H.; Keilhack, H.; Akashi, K.; Gilliland, D.G.; Neel, B.G. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell., 2005, 7, 179-191.
152. Chan, R.J; Leedy, M.B.; Munugalavadla, V.; Voorhorst, C.S.; Li, Y.; Yu, M.; Kapur R. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood, 2005, 105, 3737-3742.
153. Schubbert, S.; Lieuw, K.; Rowe, S.L.; Lee, C.M.; Li, X.; Loh, M.L.; Clapp, D.W.; Shannon, K.M. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood, 2005, 106, 311-317.
154. Braun, B.S.; Tuveson, D.A.; Kong, N.; Le, D.T.; Kogan, S.C.; Rozmus, J.; Le Beau, M.M.; Jacks, T.E.; Shannon, K.M. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl. Acad. Sci. U S A., 2004, 101, 597-602.
155. Schubbert, S.; Shannon, K.; Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer, 2007, 7, 295-308.
156. Yu, W.M.; Daino, H.; Chen, J.; Bunting, K.D.; Qu, C.K. Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling. J. Biol. Chem., 2006, 281, 5426-5434.
157. Chan, G.; Kalaitzidis, D.; Usenko, T.; Kutok, J.L.; Yang, W.; Mohi, M.G.; Neel, B.G. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood, 2009, 113, 4414-4424.
158. Xu, D.; Wang, S.; Yu, W.M.; Chan, G.; Araki, T.; Bunting, K.D.; Neel, B.G.; Qu, C.K. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood, 2010, 116, 3611-3621.
159. Miyauchi, J.; Asada, M.; Sasaki, M.; Tsunematsu, Y.; Kojima, S.; Mizutani, S. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood, 1994, 83, 2248-2254.
160. Side, L.; Taylor, B.; Cayouette, M.; Conner, E.; Thompson, P.; Luce, M.; Shannon, K. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Engl. J. Med., 1997, 336, 1713-1720.
161. Zheng, H.; Alter, S.; Qu, C.K. SHP-2 tyrosine phosphatase in human diseases. Int. J. Clin. Exp. Med., 2009, 2, 17-25.
162. Schneeberger, V.E.; Luetteke, N.; Ren, Y.; Berns, H.; Chen, L.; Foroutan, P.; Martinez, G.V.; Haura, E.B; Chen, J.; Coppola, D.; Wu, J. SHP2 E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis, 2014.
163. Coulombe, G.; Leblanc, C.; Cagnol, S.; Maloum, F.; Lemieux, E.; Perreault, N.; Feng, G.S.; Boudreau, F.; Rivard, N. Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice. Mol. Cell. Biol., 2013, 33, 2275-2284.
164. Zhang, T.; Guo, W.; Yang, Y.; Liu, W.; Guo, L.; Gu, Y.; Shu, Y.; Wang, L.; Wu, X.; Hua, Z.; Ke, Y.; Sun, Y.; Shen, Y.; Xu, Q. Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis. Sci Rep., 2013, 3, 2845.
165. Miyamoto, D.; Miyamoto, M.; Takahashi, A.; Yomogita, Y.; Higashi, H.; Kondo, S.; Hatakeyama, M. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene, 2008, 27, 3508-3515.
166. Bard-Chapeau, E.A.; Yuan, J.; Droin, N.; Long, S.; Zhang, E.E.; Nguyen, T.V.; Feng, G.S. Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection. Mol. Cell. Biol., 2006, 26, 4664-4674.
167. Bray, F.; Jemal, A.; Grey, N.; Ferlay, J.; Forman, D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol., 2012, 13, 790-801.
168. Leung, W.K.; Wu, M.S.; Kakugawa, Y.; Kim, J.J.; Yeoh, K.G.; Goh, K.L.; Wu, K.C.; Wu, D.C.; Sollano, J.; Kachintorn, U.; Gotoda, T.; Lin, J.T.; You, W.C.; Ng, E.K.; Sung, J.J.; Asia Pacific Working Group on Gastric C. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol., 2008, 9, 279-287.
169. Herrera, V.; Parsonnet, J. Helicobacter pylori and gastric adenocarcinoma. Clin. Microbiol. Infect., 2009, 15, 971-976.
170. Hatakeyama, M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat. Rev. Cancer, 2004, 4, 688-694.
171. Ding, S.Z.; Goldberg, J.B.; Hatakeyama, M. Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol., 2010, 6, 851-862.
172. Higashi, H.; Tsutsumi, R.; Muto, S.; Sugiyama, T.; Azuma, T.; Asaka, M.; Hatakeyama, M. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science, 2002, 295, 683-686.
173. Hatakeyama, M. Helicobacter pylori and gastric carcinogenesis. J. Gastroenterol., 2009, 44, 239-248.
174. Hatakeyama, M.; Higashi, H. Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis. Cancer Sci., 2005, 96, 835-843.
175. Higuchi, M.; Tsutsumi, R.; Higashi, H.; Hatakeyama, M. Conditional gene silencing utilizing the lac repressor reveals a role of SHP-2 in cagA-positive Helicobacter pylori pathogenicity. Cancer Sci., 2004, 95, 442-447.
176. Higashi, H.; Nakaya, A.; Tsutsumi, R.; Yokoyama, K.; Fujii, Y.; Ishikawa, S.; Higuchi, M.; Takahashi, A.; Kurashima, Y.; Teishikata, Y.; Tanaka, S.; Azuma, T.; Hatakeyama, M. Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation. J. Biol. Chem., 2004, 279, 17205-17216.
177. Wessler, S.; Rapp, U.R.; Wiedenmann, B.; Meyer, T.F.; Schoneberg, T.; Hocker, M.; Naumann, M. B-Raf/Rap1 signaling, but not c-Raf-1/Ras, induces the histidine decarboxylase promoter in Helicobacter pylori infection. FASEB J., 2002, 16, 417-419.
178. York, R.D.; Yao, H.; Dillon, T.; Ellig, C.L.; Eckert, S.P.; McCleskey, E.W.; Stork, P.J. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature, 1998, 392, 622-626.
179. Tseng, P.C.; Huang, W.C.; Chen, C.L.; Sheu, B.S.; Shan, Y.S.; Tsai, C.C.; Wang, C.Y.; Chen, S.O.; Hsieh, C.Y.; Lin, C.F. Regulation of SHP2 by PTEN/AKT/GSK-3beta signaling facilitates IFN-gamma resistance in hyperproliferating gastric cancer. Immunobiology, 2012, 217, 926-934.
180. Chan, R.J.; Feng, G.S. PTPN11 is the first identified protooncogene that encodes a tyrosine phosphatase. Blood, 2007, 109, 862-867.
181. Feng, G.S. Shp-2 tyrosine phosphatase: signaling one cell or many. Exp. Cell Res., 1999, 253, 47-54.
182. Kim, J.S.; Shin, O.R.; Kim, H.K.; Cho, Y.S.; An, C.H.; Lim, K.W.; Kim, S.S. Overexpression of protein phosphatase non-receptor type 11 (PTPN11) in gastric carcinomas. Dig. Dis. Sci., 2010, 55, 1565-1569.
183. Wu, C.W.; Kao, H.L.; Li, A.F.; Chi, C.W.; Lin, W.C. Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. Cancer Lett., 2006, 242, 95-103.
184. Dong, S.; Li, F.Q.; Zhang, Q.; Lv, K.Z.; Yang, H.L.; Gao, Y.; Yu, J.R. Expression and clinical significance of SHP2 in gastric cancer. J. Int. Med. Res., 2012, 40, 2083-2089.
185. Jiang, J.; Jin, M.S.; Kong, F.; Wang, Y.P.; Jia, Z.F.; Cao, D.H.; Ma, H.X.; Suo, J.; Cao, X.Y. Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer. World J. Gastroenterol., 2013, 19, 575-580.
186. Kawai, S.; Goto, Y.; Ito, L.S.; Oba-Shinjo, S.M.; Uno, M.; Shinjo, S.K.; Marie, S.K.; Ishida, Y.; Nishio, K.; Naito, M.; Hamajima, N. Significant association between PTPN11 polymorphism and gastric atrophy among Japanese Brazilians. Gastric Cancer, 2006, 9, 277-283.
187. Hishida, A.; Matsuo, K.; Goto, Y.; Naito, M.; Wakai, K.; Tajima, K.; Hamajima, N. Associations of a PTPN11 G/A polymorphism at intron 3 with Helicobactor pylori seropositivity, gastric atrophy and gastric cancer in Japanese. BMC Gastroenterol., 2009, 9, 51.
188. Hamajima, N.; Rahimov, B.; Malikov, Y.; Abdiev, S.; Ahn, K.S.; Bahramov, S.; Kawai, S.; Nishio, K.; Naito, M.; Goto, Y. Associations between a PTPN11 polymorphism and gastric atrophy--opposite in Uzbekistan to that in Japan. Asian Pac. J. Cancer Prev., 2008, 9, 217-220.
189. Hu, H.B.; Liang, X.L.; He, J.M. PTPN11 Gene polymorphisms, helicobacter pylori infection and susceptibility to gastric cancer in liuzhou area of guangxi province in China. J. Trop. Med., 2009, 9, 1233-1237.
190. Pabalan, N.; Singh, N.; Pineda, M.R.; Jarjanazi, H. Meta-analysis of the Association Between PTPN11 G/A Polymorphism at Intron 3 with Risk of Gastric Atrophy Among East Asians. J. Gastrointest. Cancer, 2014.
191. Goto, Y.; Ando, T.; Nishio, K.; Kawai, S.; Ishida, Y.; Naito, M.; Goto, H.; Hamajima, N. Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy. Int. J. Med. Sci., 2007, 4, 1-6.
192. Yang, J.J.; Cho, L.Y.; Ma, S.H.; Ko, K.P.; Shin, A.; Choi, B.Y.; Han, D.S.; Song, K.S.; Kim, Y.S.; Chang, S.H.; Shin, H.R.; Kang, D.; Yoo, K.Y.; Park, S.K. Oncogenic CagA promotes gastric cancer risk via activating ERK signaling pathways: a nested casecontrol study. PLoS One, 2011, 6, e21155.
193. Sun, X.D.; Mu, R.; Zhou, Y.S.; Dai, X.D.; Zhang, S.W.; Huangfu, X.M.; Sun, J.; Li, L.D.; Lu, F.Z.; Qiao, Y.L. Analysis of mortality rate of stomach cancer and its trend in twenty years in China. Zhonghua Zhong Liu Za Zhi, 2004, 26, 4-9.
194. Zhou, X.; Coad, J.; Ducatman, B.; Agazie, Y.M. SHP2 is upregulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology, 2008, 53, 389-402.
195. Muenst, S.; Obermann, E.C.; Gao, F.; Oertli, D.; Viehl, C.T.; Weber, W.P.; Fleming, T.; Gillanders, W.E.; Soysal, S.D. Src homology phosphotyrosyl phosphatase-2 expression is an independent negative prognostic factor in human breast cancer. Histopathology, 2013, 63, 74-82.
196. Hakak, Y.; Hsu, Y.S.; Martin, G.S. Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt. Oncogene, 2000, 19, 3164-3171.
197. Zhan, Y.; Counelis, G.J.; O'Rourke, D.M. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp. Cell Res., 2009, 315, 2343-2357.
198. Zhou, X.D.; Agazie, Y.M. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Cell Death Differ., 2008, 15, 988-996.
199. Aceto, N.; Sausgruber, N.; Brinkhaus, H.; Gaidatzis, D.; Martiny-Baron, G.; Mazzarol G.; Confalonieri, S.; Quarto, M.; Hu, G.; Balwierz, P.J.; Pachkov, M.; Elledge, S.J.; van Nimwegen, E.; Stadler, M.B.; Bentires-Alj, M. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat. Med., 2012, 18, 529-537.
200. Bocanegra, M.; Bergamaschi, A.; Kim, Y.H.; Miller, M.A.; Rajput, A.B.; Kao, J.; Langerod, A.; Han, W.; Noh, D.Y.; Jeffrey, S.S.; Huntsman, D.G.; Borresen-Dale, A.L.; Pollack, J.R. Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene, 2010, 29, 774-779.
201. Zhang, X.; Lavoie, G.; Fort, L.; Huttlin, E.L.; Tcherkezian, J.; Galan, J.A.; Gu, H.; Gygi, S.P.; Carreno, S.; Roux, P.P. Gab2 phosphorylation by RSK inhibits Shp2 recruitment and cell motility. Mol. Cell. Biol., 2013, 33, 1657-1670.
202. Jiang, C.; Hu, F.; Tai, Y.; Du, J.; Mao, B.; Yuan, Z.; Wang, Y.; Wei, L. The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol., 2012, 138, 637-646.
203. Tang, C.; Luo, D.; Yang, H.; Wang, Q.; Zhang, R.; Liu, G.; Zhou, X. Expression of SHP2 and related markers in non-small cell lung cancer: a tissue microarray study of 80 cases. Appl. Immunohistochem. Mol. Morphol., 2013, 21, 386-394.
204. Cai, P.; Guo, W.; Yuan, H.; Li, Q.; Wang, W.; Sun, Y.; Li, X.; Gu, Y. Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer. Biomed. Pharmacother., 2013.
205. Yu, S.J.; Yu, J.K.; Ge, W.T.; Hu, H.G.; Yuan, Y.; Zheng, S. SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J. Gastroenterol., 2011, 17, 2028-2036.
206. Morales, L.D.; Casillas Pavon, E.A.; Shin, J.W.; Garcia, A.; Capetillo, M.; Kim, D.J.; Lieman, J.H. Protein Tyrosine Phosphatases PTP-1B, SHP-2, and PTEN Facilitate Rb/E2FAssociated Apoptotic Signaling. PLoS One, 2014, 9, e97104.
207. Zhan, Y.; O'Rourke, D.M. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res., 2004, 64, 8292-8298.
208. Sturla, L.M.; Zinn, P.O.; Ng, K.; Nitta, M.; Kozono, D.; Chen, C.C.; Kasper, E.M. Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. Br. J. Cancer, 2011, 105, 1235-1243.
209. Liu, K.W.; Feng, H.; Bachoo, R.; Kazlauskas, A.; Smith, E.M.; Symes, K.; Hamilton, R.L.; Nagane, M.; Nishikawa, R.; Hu, B.; Cheng, S.Y. SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J. Clin. Invest., 2011, 121, 905-917.
210. Xie, H.; Huang, S.; Li, W.; Zhao, H.; Zhang, T.; Zhang, D. Upregulation of Src homology phosphotyrosyl phosphatase 2 (Shp2) expression in oral cancer and knockdown of Shp2 expression inhibit tumor cell viability and invasion in vitro. Oral Surg. Oral Med. Oral Pathol. Oral Radiol., 2014, 117, 234-242.
211. Je, E.M.; Choi, Y.J.; Yoo, N.J.; Lee, S.H. Oncogenic PTPN11 Mutations are Rare in Solid Tumors. Pathol. Oncol. Res., 2014.
212. Pathak, M.K.; Yi, T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol., 2001, 167, 3391-3397.
213. Chen, L.; Sung, S.S.; Yip, M.L.; Lawrence, H.R.; Ren, Y.; Guida, W.C.; Sebti, S.M.; Lawrence, N.J.; Wu, J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol. Pharmacol., 2006, 70, 562-570.
214. Lawrence, H.R.; Pireddu, R.; Chen, L.; Luo, Y.; Sung, S.S.; Szymanski, A.M.; Yip, M.L.; Guida, W.C.; Sebti, S.M.; Wu, J.; Lawrence, N.J. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J. Med. Chem., 2008, 51, 4948-4956.
215. Hellmuth, K.; Grosskopf, S.; Lum, C.T.; Wurtele, M.; Roder, N.; von Kries, J.P.; Rosario, M.; Rademann, J.; Birchmeier, W. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc. Natl. Acad. Sci. USA., 2008, 105, 7275-7280.
216. Liu, W.; Yu, B.; Xu, G.; Xu, W.R.; Loh, M.L.; Tang, L.D.; Qu, C.K. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). J. Med. Chem., 2013, 56, 7212-7221.
217. Liu, S.; Yu, Z.; Yu, X.; Huang, S.X.; Luo, Y.; Wu, L.; Shen, W.; Yang, Z.; Wang, L.; Gunawan, A.M.; Chan, R.J.; Shen, B.; Zhang, Z.Y. SHP2 is a target of the immunosuppressant tautomycetin. Chem. Biol., 2011, 18, 101-110.